Mining the microbiota for microbial and metabolite-based immunotherapies

Ashwin N. Skelly, Yuko Sato, Sean Kearney, Kenya Honda

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Trillions of microorganisms transit through and reside in the mammalian gastrointestinal tract each day, collectively producing thousands of small molecules and metabolites with local and systemic effects on host physiology. Identifying effector microorganisms that causally affect host phenotype and deciphering the underlying mechanisms have become foci of microbiome research and have begun to enable the development of microbiota-based therapeutics. Two complementary, reductionist approaches have commonly been used: the first starts with an immune phenotype and narrows down the microbiota to identify responsible effector bacteria, while the second starts with bacteria-derived molecules and metabolites and seeks to understand their effects on the host immune system. Together, these strategies provide the basis for the rational design of microbial and metabolite-based therapeutics that target and ameliorate immune deficits in patients.

Original languageEnglish
JournalNature Reviews Immunology
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Microbiota
Immunotherapy
Bacteria
Phenotype
Gastrointestinal Tract
Immune System
Therapeutics
Research

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Mining the microbiota for microbial and metabolite-based immunotherapies. / Skelly, Ashwin N.; Sato, Yuko; Kearney, Sean; Honda, Kenya.

In: Nature Reviews Immunology, 01.01.2019.

Research output: Contribution to journalReview article

@article{d238ab62bb0340be88f77737c00562bd,
title = "Mining the microbiota for microbial and metabolite-based immunotherapies",
abstract = "Trillions of microorganisms transit through and reside in the mammalian gastrointestinal tract each day, collectively producing thousands of small molecules and metabolites with local and systemic effects on host physiology. Identifying effector microorganisms that causally affect host phenotype and deciphering the underlying mechanisms have become foci of microbiome research and have begun to enable the development of microbiota-based therapeutics. Two complementary, reductionist approaches have commonly been used: the first starts with an immune phenotype and narrows down the microbiota to identify responsible effector bacteria, while the second starts with bacteria-derived molecules and metabolites and seeks to understand their effects on the host immune system. Together, these strategies provide the basis for the rational design of microbial and metabolite-based therapeutics that target and ameliorate immune deficits in patients.",
author = "Skelly, {Ashwin N.} and Yuko Sato and Sean Kearney and Kenya Honda",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41577-019-0144-5",
language = "English",
journal = "Nature Reviews Immunology",
issn = "1474-1733",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Mining the microbiota for microbial and metabolite-based immunotherapies

AU - Skelly, Ashwin N.

AU - Sato, Yuko

AU - Kearney, Sean

AU - Honda, Kenya

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Trillions of microorganisms transit through and reside in the mammalian gastrointestinal tract each day, collectively producing thousands of small molecules and metabolites with local and systemic effects on host physiology. Identifying effector microorganisms that causally affect host phenotype and deciphering the underlying mechanisms have become foci of microbiome research and have begun to enable the development of microbiota-based therapeutics. Two complementary, reductionist approaches have commonly been used: the first starts with an immune phenotype and narrows down the microbiota to identify responsible effector bacteria, while the second starts with bacteria-derived molecules and metabolites and seeks to understand their effects on the host immune system. Together, these strategies provide the basis for the rational design of microbial and metabolite-based therapeutics that target and ameliorate immune deficits in patients.

AB - Trillions of microorganisms transit through and reside in the mammalian gastrointestinal tract each day, collectively producing thousands of small molecules and metabolites with local and systemic effects on host physiology. Identifying effector microorganisms that causally affect host phenotype and deciphering the underlying mechanisms have become foci of microbiome research and have begun to enable the development of microbiota-based therapeutics. Two complementary, reductionist approaches have commonly been used: the first starts with an immune phenotype and narrows down the microbiota to identify responsible effector bacteria, while the second starts with bacteria-derived molecules and metabolites and seeks to understand their effects on the host immune system. Together, these strategies provide the basis for the rational design of microbial and metabolite-based therapeutics that target and ameliorate immune deficits in patients.

UR - http://www.scopus.com/inward/record.url?scp=85062881986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062881986&partnerID=8YFLogxK

U2 - 10.1038/s41577-019-0144-5

DO - 10.1038/s41577-019-0144-5

M3 - Review article

C2 - 30858494

AN - SCOPUS:85062881986

JO - Nature Reviews Immunology

JF - Nature Reviews Immunology

SN - 1474-1733

ER -